Lipella Pharmaceuticals Inc(LIPO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

LIPO Lipella Pharmaceuticals Inc

Trading 12-09 12:33:04 EST Delay

{"stockData":{"symbol":"LIPO","market":"US","secType":"STK","nameCN":"Lipella Pharmaceuticals Inc","latestPrice":0.309,"timestamp":1765301584151,"preClose":0.309,"halted":0,"volume":162,"delay":15,"floatShares":4175899,"shares":4467395,"eps":-1.759196,"marketStatus":"Trading","change":0,"latestTime":"12-09 12:33:04 EST Delay","open":0.309,"high":0.309,"low":0.309,"amount":50.80924999999999,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-1.759196,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1765314000000},"marketStatusCode":2,"adr":0,"exchange":"PINK","adjPreClose":0.309,"volumeRatio":0.041901},"requestUrl":"/m/hq/s/LIPO","defaultTab":"news","newsList":[{"id":"2577804248","title":"Lipella Pharmaceuticals Director Naoki Yoshimura Announces Retirement","url":"https://stock-news.laohu8.com/highlight/detail?id=2577804248","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577804248?lang=en_us&edition=fundamental","pubTime":"2025-10-22 04:18","pubTimestamp":1761077913,"startTime":"0","endTime":"0","summary":"Lipella Pharmaceuticals Inc. announced that Naoki Yoshimura will retire from its Board of Directors, effective December 31, 2025. The company stated that his decision was not due to any disagreement regarding its operations, policies, or practices.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lipella Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 21, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251021:nNDLSKbqN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LIPO","BK4139"],"gpt_icon":0},{"id":"2574194276","title":"Lipella Pharmaceuticals announces retirement of Chief Medical Officer Dr Michael Chancellor effective December 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2574194276","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574194276?lang=en_us&edition=fundamental","pubTime":"2025-10-10 05:01","pubTimestamp":1760043691,"startTime":"0","endTime":"0","summary":"Lipella Pharmaceuticals Inc. announced that Dr. Michael Chancellor will retire from his roles as Chief Medical Officer and as a member of the Board of Directors, effective December 4, 2025. The company stated that his decision was not due to any disagreement regarding operations, policies, or practices.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lipella Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 09, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251009:nNDL6fBjpl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LIPO"],"gpt_icon":0},{"id":"2568472968","title":"Lipella Pharmaceuticals announces final results from Phase 2a study of LP-10","url":"https://stock-news.laohu8.com/highlight/detail?id=2568472968","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568472968?lang=en_us&edition=fundamental","pubTime":"2025-09-18 20:10","pubTimestamp":1758197446,"startTime":"0","endTime":"0","summary":"Lipella Pharmaceuticals (LIPO) announced final results from its completed Phase 2a multicenter, dose-ranging study evaluating LP-10, a proprietary ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/lipella-pharmaceuticals-announces-final-results-from-phase-2a-study-of-lp-10-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/lipella-pharmaceuticals-announces-final-results-from-phase-2a-study-of-lp-10-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LIPO"],"gpt_icon":0},{"id":"2568741574","title":"Lipella Pharmaceuticals Announces Positive Final Results From Phase 2a Study of Lp-10 in Oral Lichen Planus","url":"https://stock-news.laohu8.com/highlight/detail?id=2568741574","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568741574?lang=en_us&edition=fundamental","pubTime":"2025-09-18 20:00","pubTimestamp":1758196801,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250918:nTUA3DSTLM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LIPO","BK4139"],"gpt_icon":0},{"id":"1132908882","title":"Shenzhen Longli Technology's LIPO Technology Powers Meizu 22 Flagship Smartphone","url":"https://stock-news.laohu8.com/highlight/detail?id=1132908882","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1132908882?lang=en_us&edition=fundamental","pubTime":"2025-09-16 21:01","pubTimestamp":1758027711,"startTime":"0","endTime":"0","summary":"Shenzhen Longli Technology Co.,Ltd.'s LIPO ultra-narrow bezel technology has been successfully applied to the Meizu 22, marking an innovative breakthrough for mutual success. On September 15th, a...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LIPO","BK4139","BK0214","300752"],"gpt_icon":0},{"id":"2567111928","title":"Lipella Pharmaceuticals to Present Final Phase 2a Trial Results of LP-10 for Oral Lichen Planus at Upcoming Life Sciences Virtual Investor Forum","url":"https://stock-news.laohu8.com/highlight/detail?id=2567111928","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567111928?lang=en_us&edition=fundamental","pubTime":"2025-09-15 20:01","pubTimestamp":1757937715,"startTime":"0","endTime":"0","summary":"Lipella Pharmaceuticals to Present Final Phase 2a Trial Results of LP-10 for Oral Lichen Planus at Upcoming Life Sciences Virtual Investor Forum. Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, has announced that its Chief Executive Officer, Jonathan Kaufman, will present a corporate overview and the final results from the Phase 2a trial of LP-10 in treating oral lichen planus. The presentation will take place at the Zacks SCR Life Sciences Virtual Investor Forum on September 18, 2025, at 12:30 PM EDT. This live, interactive online event will allow investors to ask questions in real-time, with an archived webcast available for those unable to attend. Interested participants are encouraged to pre-register and complete an online system check to facilitate their participation.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250915:nNDL3kXJQQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LIPO","BK4139"],"gpt_icon":0},{"id":"2546223379","title":"Lipella Pharmaceuticals Inc. Delisted from Nasdaq, Actively Exploring Relisting Options on National Exchanges","url":"https://stock-news.laohu8.com/highlight/detail?id=2546223379","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546223379?lang=en_us&edition=fundamental","pubTime":"2025-06-26 03:15","pubTimestamp":1750878923,"startTime":"0","endTime":"0","summary":"Lipella Pharmaceuticals Inc. has been delisted from Nasdaq due to non-compliance with certain listing rules related to private placement transactions completed between December 2024 and March 2025. This delisting was not a result of financial instability but rather due to issues with the issuance of voting convertible preferred stock and warrants. As of June 19, 2025, Lipella's shares are now traded on the OTC Pink Market under the symbol LIPO. The company is actively exploring options to relist on a national exchange and plans to submit an initial listing application soon. Additionally, Lipella expects to report final topline data from the fully enrolled Phase 2a trial of LP-310 in the second half of 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250625:nNDL1KC3N0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LIPO","BK4139"],"gpt_icon":0},{"id":"2545177200","title":"BRIEF-Lipella Pharmaceuticals Announces Delisting From Nasdaq Capital Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2545177200","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545177200?lang=en_us&edition=fundamental","pubTime":"2025-06-21 03:44","pubTimestamp":1750448674,"startTime":"0","endTime":"0","summary":"BRIEF-Lipella Pharmaceuticals Announces Delisting From Nasdaq Capital MarketJune 20 (Reuters) - Lipella Pharmaceuticals Inc LIPO.PK:LIPELLA PHARMACEUTICALS ANNOUNCES DELISTING FROM NASDAQ CAPITAL MARK","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250620:nFWN3SN066:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LIPO"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.lipella.com","description":"Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It is developing LP-10, a formulation of tacrolimus that is in Phase IIa clinical trial for patients with radiation-induced hemorrhagic cystitis; and LP-310, a formulation of tacrolimus for the treatment of oral lichen planus. Lipella Pharmaceuticals Inc. was incorporated in 2005 and is based in Pittsburgh, Pennsylvania.","exchange":"PINK","name":"Lipella Pharmaceuticals Inc","nameEN":"Lipella Pharmaceuticals Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Lipella Pharmaceuticals Inc(LIPO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Lipella Pharmaceuticals Inc(LIPO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Lipella Pharmaceuticals Inc,LIPO,Lipella Pharmaceuticals Inc股票,Lipella Pharmaceuticals Inc股票老虎,Lipella Pharmaceuticals Inc股票老虎国际,Lipella Pharmaceuticals Inc行情,Lipella Pharmaceuticals Inc股票行情,Lipella Pharmaceuticals Inc股价,Lipella Pharmaceuticals Inc股市,Lipella Pharmaceuticals Inc股票价格,Lipella Pharmaceuticals Inc股票交易,Lipella Pharmaceuticals Inc股票购买,Lipella Pharmaceuticals Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Lipella Pharmaceuticals Inc(LIPO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Lipella Pharmaceuticals Inc(LIPO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction